NEW YORK, Feb 13 – Bioinformatics tool provider Pharmacopeia said Tuesday it had promoted Michael Stapleton to the position of chief operating officer for the company’s software division and Stephen Spearman to the position of chief operating officer for the company’s drug discovery business.
The Princeton, NJ-based company decided to create two COO positions for the different divisions following the resignation of Saiid Zarrabian in December.
“Given the current size and growth potential of our drug discovery and software businesses, we felt it was important to put experienced leaders at the helm of each business,” Joseph Mollica, Pharmacopeia's CEO, said in a statement.
Stapleton, who has been with Pharmacopeia for the last 10 years, most recently served as the executive vice president of software operations. The division makes software for molecular modeling and simulation, gene sequence analysis, cheminformatics, bioinformatics, knowledge management, and decision support.
Spearman has worked for Pharmacopeia since 1996 and was most recently executive vice president of discovery technologies. The company’s drug discovery business helps to optimize lead compounds for customers.